The Impella 2.5 left percutaneous (LP), a relatively new transvalvular assist device, challenges the position of the intra-aortic balloon pump (IABP), which has a long record in supporting patients after myocardial infarction and cardiac surgery. However, while more costly and more demanding in management, the advantages of the Impella 2.5 LP are yet to be established. The aim of this study was to evaluate the benefits of the 40 cc IABP and the Impella 2.5 LP operating at 47 000 rpm in vitro, and compare their circulatory support capabilities in terms of cardiac output, coronary flow, cardiac stroke work, and arterial blood pressure. Clinical scenarios of cardiogenic preshock and cardiogenic shock (CS), with blood pressure depression, lower...
Patients who suffer cardiogenic shock after cardiac arrest have a very poor prognosis. Left ventricu...
The high cost of ventricular assist devices results in poor cost-effectiveness when used as a short-...
The use of mechanical circulatory support (MCS) to provide acute haemodynamic support for cardiogeni...
The Impella 2.5 left percutaneous (LP), a relatively new transvalvular assist device, challenges the...
The Impella 2.5 left percutaneous (LP), a relatively new transvalvular assist device, challenges the...
International audienceBACKGROUND: Percutaneous assist devices may be used as a bridge to recovery in...
The PUCA II pump is a minimally invasive intra-arterial left ventricular assist device that can be u...
Background Historically, the intra-aortic balloon pump (IABP) has been the primary means of providin...
In modern coronary bypass surgery, new objectives have been set based upon a minimal invasive approa...
AIMS Patients suffering from cardiogenic shock (CS) have a high mortality and morbidity. The Impe...
ObjectivesThe aim of this study was to test whether the left ventricular assist device (LVAD) Impell...
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure c...
Patients who suffer cardiogenic shock after cardiac arrest have a very poor prognosis. Left ventricu...
The high cost of ventricular assist devices results in poor cost-effectiveness when used as a short-...
The use of mechanical circulatory support (MCS) to provide acute haemodynamic support for cardiogeni...
The Impella 2.5 left percutaneous (LP), a relatively new transvalvular assist device, challenges the...
The Impella 2.5 left percutaneous (LP), a relatively new transvalvular assist device, challenges the...
International audienceBACKGROUND: Percutaneous assist devices may be used as a bridge to recovery in...
The PUCA II pump is a minimally invasive intra-arterial left ventricular assist device that can be u...
Background Historically, the intra-aortic balloon pump (IABP) has been the primary means of providin...
In modern coronary bypass surgery, new objectives have been set based upon a minimal invasive approa...
AIMS Patients suffering from cardiogenic shock (CS) have a high mortality and morbidity. The Impe...
ObjectivesThe aim of this study was to test whether the left ventricular assist device (LVAD) Impell...
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure c...
Patients who suffer cardiogenic shock after cardiac arrest have a very poor prognosis. Left ventricu...
The high cost of ventricular assist devices results in poor cost-effectiveness when used as a short-...
The use of mechanical circulatory support (MCS) to provide acute haemodynamic support for cardiogeni...